Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Background: Topical tretinoin’s role in acne has been established through evidence-based guidelines. Cutaneous irritation and potential to cause or exacerbate postinflammatory hyperpigmentation (PIH) may limit use.Objective: Evaluate safety and tolerability of novel polymeric formulation of tretinoin 0.05% lotion in moderate-to-severe acne.Methods: One thousand six hundred and forty patients randomized to tretinoin 0.05% lotion or vehicle in two double-blind placebo-controlled 12-week studies. Investigator-evaluated cutaneous safety (erythema and scaling) and patient-reported tolerability (itching, burning/stinging) assessed using a scale of 0 (none) to 3 (severe). Hyper- and hypo-pigmentation evaluated at each study visit. A number of subpopulations were investigated.Results: Tretinoin 0.05% lotion was considered safe and very well tolerated. Only application site pain (3.1%), dryness (3.7%) and erythema (1.4%) were reported by >1% or patients. Treatment-related adverse events were particularly rare (≤2%) in Hispanic and male subpopulations, and lower in adult females. The severity of cutaneous safety and tolerability scores remained <0.5 (where 1 = mild) and were generally lower than baseline severity. Tretinoin 0.05% lotion did not appear to cause or exacerbate PIH.Conclusions: A novel polymeric formulation of tretinoin 0.05% lotion provides a highly favorable safety and tolerability profile, with an incidence of erythema, dryness, and skin burning lower than that previously reported with other formulations of tretinoin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatmentemergent adverse events leading to discontinuation at 12 weeks were low (1.4%) in 3 RCTs.63,80,155”
From Guidelines of care for the management of acne vulgaris (2024) · cites this paper as [155]
Citations
Cites
Guidelines of care for the management of acne vulgaris
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.037 · Cited by 1,597
Self-citationEuropean Evidence‐based (S3) Guidelines for the Treatment of Acne
Nast, A., Dréno, B., Bettoli, V., Degitz, K., Erdmann, R., Finlay, A. Y., Ganceviciene, R., Haedersdal, M., Layton, A., López‐Estebaranz, J. L., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04374.x · Cited by 426
Perkins, A. C., Cheng, C. E., Hillebrand, G. G., Miyamoto, K., & Kimball, A. B. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03919.x · Cited by 172
Why Topical Retinoids Are Mainstay of Therapy for Acne
Leyden, J., Stein-Gold, L., & Weiss, J. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0185-2 · Cited by 164
Acne in ethnic skin: special considerations for therapy
Callender, V. D. (2004) · Dermatologic Therapy · doi:10.1111/j.1396-0296.2004.04019.x · Cited by 121
Melanin Pigmentary Disorders: Treatment Update
Ortonne, J. P., & Passeron, T. (2005) · Dermatologic Clinics · doi:10.1016/j.det.2005.01.001 · Cited by 100
Culp, L., Moradi Tuchayi, S., Alinia, H., & Feldman, S. R. (2015) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475415591117 · Cited by 40
Tanghetti, E. A., Dhawan, S., Green, L., Rosso, J. Q. D., Draelos, Z. D., Leyden, J., Shalita, A. R., Glaser, D. A., Grimes, P. E., WEBSTER, G. F., et al. (2010) · PubMed · Cited by 37
Tyring, S. K., Kircik, L., Pariser, D. M., Guenin, E., Bhatt, V. R., & Pillai, R. (2018) · PubMed · Cited by 28
Self-citationShort contact therapy of acne with tretinoin
Veraldi, S., Barbareschi, M., Benardon, S., & Schianchi, R. (2012) · Journal of Dermatological Treatment · doi:10.3109/09546634.2012.751085 · Cited by 26
Research works printed but not linked: 10
- Tanghetti E, 2010, J Drugs Dermatol, 9, 549
- Dosik JS, 2007, J Drugs Dermatol, 6, 632
- Leyden J, 2009, J Drugs Dermatol, 8, 383
- Tyring SK, 2018, J Drugs Dermatol, 17, 602
- Webster G, 2009, Cutis, 83, 146
- Nighland M, 2008, J Drugs Dermatol, 7, s2
- Draelos ZD, 2017, J Drugs Dermatol, 16, 591
- Tanghetti EA, 2018, J Drugs Dermatol, 17, 1192
- Taylor SC, 2018, J Drugs Dermatol, 17, 160
- Kircik L, J Drugs Dermatol
Cited by
Guidelines of care for the management of acne vulgaris
Reynolds, R. V., Yeung, H., Cheng, C. E., Cook-Bolden, F., Desai, S. R., Druby, K. M., Freeman, E. E., Keri, J. E., Stein Gold, L. F., Tan, J. K. L., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.12.017 · Cited by 518
Metadata
- Authors
- Harper, J. C., Roberts, W. E., Zeichner, J. A., Guenin, E., Bhatt, V., & Pillai, R.
- Affiliations
- The Dermatology and Skin Care Center of Birmingham, Birmingham, AL, USA;
- Generational and Cosmetic Dermatology, Mirage, CA, USA;
- Mount Sinai Hospital (US)
- Ortho Dermatologics, Bridgewater, NJ, USA;
- Bausch Health (United States) (US)
- Corresponding author
- Harper, Julie C
- Venue
- Journal of Dermatological Treatment
- Publisher
- Informa UK Limited
- Published
- 2019-04-02
- Volume
- 31
- Issue
- 2
- Pages
- 160-167
- ISSN
- 0954-6634 (ISSN-L)
- 1471-1753
- OpenAlex
- W2931024703
- Semantic Scholar
- c777507ff723e0aafb208a141dd569424a9e0b0c
- Cited by
- 16
- References
- 22
- Citations by year
- 2024: 3 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 4
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Dermatological Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
- Keywords
- all-trans retinoic acid, acne, topical retinoids, once-daily treatment, skin irritation, post-inflammatory hyperpigmentation, skin tolerability, erythema, dryness, subpopulation differences, Hispanic patients, sex differences
- MeSH terms
- Acne Vulgaris, Adolescent, Adult, Child, Double-Blind Method, Drug Administration Schedule, Drug Tolerance, Female, Humans, Keratolytic Agents, Male, Middle Aged, Pain, Pruritus, Severity of Illness Index, Tretinoin, Placebo Effect, Treatment Outcome, Hyperpigmentation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups. https://app.cochat.ai/papers/10.1080/09546634.2019.1587884
- The paper
- Harper, J. C., Roberts, W. E., Zeichner, J. A., Guenin, E., Bhatt, V., & Pillai, R. (2020). Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups. Journal of Dermatological Treatment. https://doi.org/10.1080/09546634.2019.1587884
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.